Covered recipient · General Payments record
CAROL SWETLIK
General Payments · PY2023–2024
$7,216.19
- Reported across 20 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $5,365.00 | 2 |
| Food and Beverage | $1,376.09 | 14 |
| Travel and Lodging | $299.79 | 1 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Amgen Inc. | $3,341.42 | 7 |
| Genentech USA, Inc. | $3,251.11 | 5 |
| Celgene Corporation | $173.01 | 2 |
| Alexion Pharmaceuticals, Inc. | $141.46 | 2 |
| Genentech, Inc. | $133.88 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
Program year 2024 2023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Alexion Pharmaceuticals, Inc. | $115.32 | 02/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110512364 | CMS |
| Alexion Pharmaceuticals, Inc. | $26.14 | 05/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110516136 | CMS |
| Amgen Inc. | $299.79 | 04/11/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1111719889 | CMS |
| Amgen Inc. | $110.00 | 04/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111719887 | CMS |
| Amgen Inc. | $150.00 | 04/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111719891 | CMS |
| Amgen Inc. | $50.00 | 04/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111719893 | CMS |
| Amgen Inc. | $70.00 | 04/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111719895 | CMS |
| Amgen Inc. | $186.63 | 04/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111719897 | CMS |
| Amgen Inc. | $2,475.00 | 04/12/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1111719899 | CMS |
| Celgene Corporation | $129.21 | 03/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101183949 | CMS |
| Celgene Corporation | $43.80 | 05/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101183955 | CMS |
| Genentech USA, Inc. | $2,890.00 | 04/13/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1132984603 | CMS |
| Genentech USA, Inc. | $43.90 | 04/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132984607 | CMS |
| Genentech USA, Inc. | $58.26 | 04/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132984611 | CMS |
| Genentech USA, Inc. | $169.08 | 04/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132984615 | CMS |
| Genentech USA, Inc. | $89.87 | 04/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132984619 | CMS |
| Genentech, Inc. | $133.88 | 03/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132984623 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2023, 2024
- Source files
- Dataset page · Bulk file · PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.